The U.S. Health Resources and Services Administration’s (HRSA) proposed replacement for its year-old 340B administrative dispute resolution (ADR) process has been under White House review for almost 100 days—nearly a month longer that the anticipated release date announced in November.
HRSA sent the proposed rule to the Office of Management and Budget (OMB) for approval on Nov. 18, 2021. At that time, it said it expected to publish the proposed rule in January. HRSA said the new rule “better aligns with the President’s priorities on drug pricing, better reflects the current state of the 340B program, and seeks to correct procedural deficiencies in the 340B ADR process.”
The U.S. Health Resources and Services Administration’s (HRSA) proposed replacement for its year-old 340B administrative dispute resolution (ADR) process has been under White House review for almost 100 days—nearly a month longer that the anticipated release date announced in November.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
